Ticagrelor 90 mg is an oral antiplatelet medicine used to lower the risk of clot-related heart and stroke events in selected adults, often after acute coronary syndrome or coronary stent placement. It helps stop platelets from clumping together. That matters because platelet clots can block narrowed or recently treated arteries. This article explains how it works, how clinicians commonly dose it, what side effects to watch for, and which safety questions to raise with your care team.
Key Takeaways
- Primary role: It helps reduce platelet-driven clot formation after certain heart events.
- Common schedule: Many adults take it twice daily with low-dose aspirin.
- Main risks: Bleeding and shortness of breath are important reported effects.
- Procedure planning: Surgery or dental work may require advance review.
- Interaction checks: CYP3A drugs, grapefruit, NSAIDs, and anticoagulants need caution.
Where Ticagrelor 90 mg Fits in Heart Care
Ticagrelor is a P2Y12 receptor antagonist, which means it blocks a platelet signal involved in clot formation. Platelets are small blood cells that help form clots after injury. In coronary artery disease, they can also contribute to harmful clots inside narrowed or treated arteries.
Clinicians may prescribe Ticagrelor 90 mg after acute coronary syndrome (ACS), including heart attack or unstable angina, and after some percutaneous coronary intervention (PCI) procedures such as stent placement. The goal is to lower the chance of events such as heart attack, stroke, or stent thrombosis. Stent thrombosis is a clot that forms inside or near a stent and can be dangerous.
Some people know the medicine by the brand name Brilinta. Ticagrelor is the active ingredient, while Brilinta is a branded formulation. For product-level context, see Ticagrelor or Brilinta. These pages can help you recognize names and strengths, but your prescriber decides whether this medicine fits your diagnosis and bleeding risk.
Why it matters: Missing doses or stopping early can change clot protection, especially soon after a stent.
How This Antiplatelet Medicine Works
Ticagrelor works by reversibly blocking the P2Y12 adenosine diphosphate receptor on platelets. In plain language, it reduces the “stickiness signal” that tells platelets to gather and form a clot. Because the effect is reversible, platelet activity can recover after the medicine is stopped, although timing varies by person and clinical setting.
People often ask whether ticagrelor is a blood thinner. It is commonly grouped with blood thinners, but more precisely it is an antiplatelet medicine. Antiplatelets act on platelets. Anticoagulants, another type of blood thinner, act on clotting proteins. This distinction matters because side effects, interactions, and procedure planning differ between these drug classes.
Ticagrelor is also different from some older P2Y12 inhibitors because it does not need activation through the same metabolic pathway before it works. That feature helps explain why clinicians may choose it in acute cardiac settings. It does not mean it is safer for every person. The right antiplatelet depends on the event being treated, bleeding risk, other medicines, age, kidney or liver considerations, and upcoming procedures.
Typical Dosing Pattern and Aspirin Pairing
For many adults after ACS, treatment begins with a loading dose in an acute-care setting, followed by maintenance dosing. A common maintenance schedule is ticagrelor 90 mg twice daily, often taken with low-dose aspirin. Your exact plan may differ based on the reason for treatment, timing after the event, and your clinician’s assessment.
The phrase Brilinta 90 mg dosage per day often appears in searches, but the key point is frequency. Many regimens use one 90 mg tablet twice a day, not one tablet once daily. Doses are usually spaced consistently to maintain platelet inhibition. Tablets can generally be taken with or without food, unless your prescriber or pharmacist gives different instructions.
Low-dose aspirin is commonly used with ticagrelor as dual antiplatelet therapy. Higher aspirin doses may reduce ticagrelor’s effectiveness in some labeled settings, so the aspirin dose should be reviewed rather than guessed. Tell your care team about all aspirin-containing products, including over-the-counter pain relievers and combination cold medicines.
Missed doses and daily routines
If you miss a dose, follow the instructions from your prescription label or care team. Do not double up unless a clinician specifically tells you to do so. A pill organizer, phone alarm, or written medication list can help reduce missed doses, especially when other heart medicines are also prescribed.
If swallowing is difficult, ask a pharmacist or prescriber for medicine-specific instructions. Do not crush or alter tablets unless a qualified professional confirms it is appropriate for your situation. This is especially important after hospital discharge, when medication lists often change quickly.
Side Effects: Common Issues and Warning Signs
The most important ticagrelor side effects involve bleeding, because the medicine reduces platelet clotting. Mild bruising or small nosebleeds can occur, but serious bleeding needs urgent review. Seek prompt medical help for black or bloody stools, vomiting blood, coughing blood, blood in urine, severe headache after a fall, or bleeding that will not stop.
Shortness of breath is another reported effect. Some people describe air hunger, chest tightness, or feeling unable to take a satisfying breath. Mild symptoms may improve, but new, severe, worsening, or activity-limiting breathing problems should be assessed. This is especially important for people with asthma, chronic obstructive pulmonary disease, heart failure, or recent heart attack symptoms.
Other reported effects can include dizziness, nausea, headache, and higher uric acid levels. Rare rhythm-related concerns, such as slow heartbeat or pauses, may matter more in people with underlying conduction disease. Tell your clinician about fainting, near-fainting, new palpitations, or unexplained weakness.
Brilinta side effects and generic ticagrelor side effects are generally discussed together because both refer to the same active ingredient. However, inactive ingredients, tablet appearance, and manufacturer details can vary. If a symptom starts after a formulation change, document the timing and ask a pharmacist to review the product.
Contraindications, Interactions, and Procedure Planning
Ticagrelor is not appropriate for everyone. Important contraindications include active pathological bleeding, a history of intracranial hemorrhage, and severe liver impairment. People with recent major bleeding, high fall risk, or planned invasive procedures may need a careful risk-benefit discussion before continuing therapy.
Drug interactions deserve close attention. Strong CYP3A inhibitors can raise ticagrelor exposure, while strong CYP3A inducers can reduce exposure and may weaken effect. Examples may include certain antifungals, antibiotics, seizure medicines, and rifamycin antibiotics. Grapefruit products can also affect CYP3A metabolism and may increase exposure.
Bleeding risk can rise when ticagrelor is combined with anticoagulants, nonsteroidal anti-inflammatory drugs (NSAIDs), or other medicines that affect clotting. This does not mean combinations are always forbidden. It means they require a deliberate clinical reason and monitoring plan. Tell your prescriber before starting ibuprofen, naproxen, herbal supplements, or new over-the-counter products.
Statins are frequently used after ACS or stent placement, and they may be prescribed with ticagrelor. If you take a statin, report unexplained muscle pain, weakness, or dark urine. Your clinician can decide whether symptoms, dose, or medication selection need review.
When surgery or dental work is planned
Many readers ask when to stop ticagrelor before surgery. The answer depends on the procedure, bleeding risk, time since stent placement, and reason for antiplatelet therapy. Do not stop it on your own. Instead, contact the clinician managing your stent or ACS care before elective surgery, dental extraction, endoscopy, or spinal procedures.
Procedure planning often involves the cardiology team, surgeon, dentist, anesthesiologist, and primary care clinician. They may decide whether aspirin continues, whether ticagrelor pauses, and when it restarts. Bring a current medication list to every preoperative visit so the team can identify antiplatelet therapy early.
How Long Treatment May Continue After a Stent
Duration after a heart attack or stent is individualized. Many patients receive dual antiplatelet therapy through the higher-risk period after ACS or PCI, then reassess therapy with their cardiology team. The decision weighs clot risk against bleeding risk. Stent type, procedure complexity, prior heart events, age, kidney function, and bleeding history can all influence the plan.
Some people remain on ticagrelor beyond the first year, while others switch medicines or stop P2Y12 therapy under medical supervision. Lower-strength ticagrelor may be considered in certain extended-treatment situations, but that decision must be clinician-led. Do not interpret another person’s duration as a safe plan for you.
If ticagrelor is difficult to tolerate, clinicians may consider another antiplatelet option. For background on related medicines, review Clopidogrel 75 mg or Prasugrel 10 mg. You can also compare product context for Clopidogrel when discussing alternatives with your pharmacist or prescriber.
Quick tip: Ask your cardiology team to write the planned review date on your medication list.
Practical Questions to Bring to Your Clinician
Good follow-up questions can prevent confusion after discharge. This is useful because antiplatelet plans often involve several medicines, refill timing, and procedure restrictions. Use the list below to prepare for your next appointment without changing treatment on your own.
- Treatment reason: Ask which diagnosis or procedure the medicine is covering.
- Expected duration: Ask when the plan will be reassessed.
- Aspirin dose: Confirm the exact daily aspirin amount.
- Bleeding plan: Ask which symptoms require urgent care.
- Procedure instructions: Ask who should approve any pause.
- Interaction review: Bring all prescription and nonprescription products.
Access questions may also come up if a prescription continues after hospital discharge. CanadianInsulin.com functions as a prescription referral platform, and prescription details may be confirmed with the prescriber where required. Dispensing and fulfillment are handled by licensed third-party pharmacies where permitted. For broader browsing, the Cardiovascular product category and Cardiovascular Articles collection can help you review related heart medication topics.
Authoritative Sources
For official prescribing details, review the FDA-approved Brilinta prescribing information, including indications, warnings, and interaction language.
For patient-friendly safety details, the NHS provides plain-language ticagrelor side effect guidance covering common reactions and cautions.
For general medication education, MedlinePlus offers a consumer ticagrelor medicine summary from the U.S. National Library of Medicine.
Recap
Ticagrelor 90 mg helps reduce platelet clumping after selected heart events and stent procedures. Many regimens use twice-daily dosing with low-dose aspirin, but the exact plan must come from your clinician. Bleeding, shortness of breath, interactions, and surgery planning are the main safety issues to understand. Keep an updated medication list, report concerning symptoms promptly, and ask before stopping or changing any antiplatelet medicine.
This content is for informational purposes only and is not a substitute for professional medical advice.
